Michael Kühn: Grateful for the invitation to return to MSKCC to discuss menin inhibition
Michael Kühn, Chief of Acute Leukemia Service at University Medical Center Mainz, shared a post on LinkedIn by Gregory Nalesnik, Pediatric Oncologist at Memorial Sloan Kettering Cancer Center, adding:
“I am incredibly proud and grateful for the invitation to return to Memorial Sloan Kettering Cancer Center to discuss menin inhibition in leukemia. I extend my heartfelt thanks to Sheng Cai, Gregory Nalesnik, and all my wonderful hematology colleagues for the stimulating and productive discussion on this topic we began exploring a decade ago in the Scott Armstrong lab at MSK. It is immensely rewarding to witness the approval of the first menin inhibitor for AML treatment and to see it making a meaningful difference for our patients.”
Quoting Gregory Nalesnik’s post below:
“Thank you Dr. Michael Kühn for an exceptional grand rounds presentation on Menin inhibitor therapy for high-risk AML! Your research on resistance pathways is very insightful. I am excited to see what the future holds for the treatment of this aggressive type of leukemia.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023